Assessing PFS and alternative endpoints for advanced cancer clinical trials [Video]

Jurjen Versluis, MD, PhD, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses progression-free survival (PFS) as an endpoint in advanced cancer clinical trials and other endpoints that may be suitable alternatives. Dr Verluis emphasizes the importance of long-term follow-up to assess overall survival (OS) benefits, as well as the validation of alternative endpoints such as measurable residual disease (MRD). This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.